IMVT

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Immunovant Inc

NASDAQ | IMVT

23.43

USD

$0.00

(

0.00%

)

At Close (As of Nov 5, 2025)

$4.22B

Market Cap

-

P/E Ratio

-2.84

EPS

$31.66

52 Week High

$12.72

52 Week Low

HEALTHCARE

Sector

IMVT Chart

Recent Chart
Price Action

IMVT Technicals

Tags:

IMVT Earnings

Yearly Income Statement (As of Mar 31, 2025)

Field Value (USD)
Gross Profit -$377K
Total Revenue $0
Cost Of Revenue $377K
Costof Goods And Services Sold $377K
Operating Income -$438M
Selling General And Administrative $77M
Research And Development $361M
Operating Expenses $438M
Investment Income Net -
Net Interest Income $25M
Interest Income $25M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $377K
Income Before Tax -$413M
Income Tax Expense $891K
Interest And Debt Expense -
Net Income From Continuing Operations -$414M
Comprehensive Income Net Of Tax -
Ebit -$413M
Ebitda -$413M
Net Income -$414M

Revenue & Profitability

Earnings Performance

IMVT Financials

yearly Balance Sheet (As of Mar 31, 2025)

Field Value (USD)
Total Assets $776M
Total Current Assets $768M
Cash And Cash Equivalents At Carrying Value $714M
Cash And Short Term Investments $714M
Inventory -
Current Net Receivables $2.5M
Total Non Current Assets $8.6M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $51M
Other Non Current Assets -
Total Liabilities $69M
Total Current Liabilities $69M
Current Accounts Payable $18M
Deferred Revenue -
Current Debt -
Short Term Debt $98K
Total Non Current Liabilities $1.1M
Capital Lease Obligations $98K
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $98K
Other Current Liabilities $51M
Other Non Current Liabilities -
Total Shareholder Equity $707M
Treasury Stock -
Retained Earnings -$1.2B
Common Stock $16K
Common Stock Shares Outstanding $152M

yearly Cash Flow (As of Mar 31, 2025)

Field Value (USD)
Operating Cashflow -$376M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $377K
Capital Expenditures $759K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$759K
Cashflow From Financing $454M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$414M

yearly Income Statement (As of Mar 31, 2025)

Field Value (USD)
Gross Profit -$377K
Total Revenue $0
Cost Of Revenue $377K
Costof Goods And Services Sold $377K
Operating Income -$438M
Selling General And Administrative $77M
Research And Development $361M
Operating Expenses $438M
Investment Income Net -
Net Interest Income $25M
Interest Income $25M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $377K
Income Before Tax -$413M
Income Tax Expense $891K
Interest And Debt Expense -
Net Income From Continuing Operations -$414M
Comprehensive Income Net Of Tax -
Ebit -$413M
Ebitda -$413M
Net Income -$414M

IMVT News

IMVT Profile

Immunovant Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Immunovant, Inc. is a clinical-stage biopharmaceutical company headquartered in New York, dedicated to developing innovative monoclonal antibody therapies for autoimmune disorders. Its lead candidate, batoclimab, specifically targets critical pathways implicated in these diseases and is currently being evaluated in multiple clinical trials to establish its efficacy and safety profile. With a promising pipeline and a strategic focus on addressing significant unmet medical needs within immunology, Immunovant represents a compelling opportunity for institutional investors seeking to invest in growth-oriented biopharmaceuticals.

CHR
-39.11%
$0.08
NVVE
+14.42%
$0.24
MTC
+260.19%
$1.09
ASST
+19.20%
$1.49
PFE
-1.45%
$24.30
VHAI
0.00%
$0.00
RIVN
+24.05%
$15.50
LNAI
+60.07%
$1.33
PLUG
-8.36%
$2.52
NVDA
+1.26%
$201.21
RUBI
-54.72%
$0.27
SMX
+42.04%
$2.08
YDKG
-7.03%
$0.05
SLDP
+52.44%
$8.55
BYND
-2.25%
$1.30
AXDX
-61.36%
$0.03
PLTR
-0.75%
$189.30
GPUS
-7.02%
$0.34
TSLA
+4.39%
$463.77
F
+3.66%
$13.25
AMD
+3.62%
$259.11
ADAP
-15.14%
$0.05
DNN
-1.86%
$2.68
WTO
-5.83%
$0.04
PINS
-22.07%
$25.64
BITF
+2.60%
$3.94
BMNR
-7.93%
$39.46
INTC
+3.59%
$38.36
CIFR
+7.46%
$24.19
AAL
+6.79%
$13.51
NFE
+13.12%
$1.52
SMCI
-9.70%
$42.80
ETHD
-15.40%
$4.44
ONDS
-0.75%
$5.91
RXRX
-0.40%
$4.98
SOFI
+1.48%
$29.80
TEVA
+22.06%
$24.97
RMBL
+60.50%
$3.21
JOBY
-9.55%
$14.76
DVLT
-8.44%
$1.62
ADD
-25.47%
$0.05
ACHR
-0.15%
$9.54
T
+0.14%
$24.47
SRM
+53.27%
$10.30
BAC
-1.44%
$52.76
SNAP
+0.06%
$7.47
KVUE
+2.12%
$16.30
EPWK
-6.81%
$0.06
QS
+10.91%
$17.12
RIG
+0.38%
$3.91
FUBO
+9.10%
$4.01
TLRY
+2.41%
$1.27
VALE
+3.24%
$12.32
ZDAI
+18.33%
$0.54
NAKA
-11.88%
$0.78
KDLY
-11.88%
$0.78
IREN
+10.35%
$73.53
BTG
+1.00%
$4.04
CAN
+12.16%
$1.24
APLD
-5.50%
$31.06
APPS
+21.45%
$7.19
WLGS
-5.57%
$0.04
WULF
+0.39%
$15.07
U
+14.50%
$41.07
NVO
-0.87%
$47.82
MARA
+3.29%
$17.16
HIMS
+4.67%
$44.79
GRAB
-0.08%
$5.78
ETWO
0.00%
$3.30
RGTI
+4.81%
$36.87
RDHL
+13.88%
$1.23
BURU
-3.24%
$0.28
NIO
+3.00%
$7.37
PCG
+1.11%
$16.34
NOK
+0.70%
$6.85
COMP
+7.45%
$8.36
BTBT
+2.06%
$3.24
HTZ
-4.60%
$6.42
WBD
+1.77%
$23.00
MU
-7.10%
$218.03
BW
+36.89%
$5.12
AFMD
-34.94%
$0.18
NCLH
-0.01%
$18.78
IONZ
-8.42%
$4.09
HBAN
-0.65%
$15.27
CMBM
-12.34%
$2.84
AG
-7.48%
$10.69
AMZN
0.00%
$249.31
QBTS
+4.60%
$31.11
RIOT
-3.78%
$18.54
SOLT
-13.39%
$11.06
PLTD
+1.02%
$6.41
PLTZ
+3.12%
$6.25
AAPL
+0.20%
$270.58
NVTS
-7.60%
$9.66
BBD
+2.81%
$3.50
SOUN
+2.54%
$15.51
MSPR
-24.83%
$0.49
ABEV
+1.04%
$2.41
CMG
+1.15%
$32.10
CHR
-39.11%
$0.08
NVVE
+14.42%
$0.24
MTC
+260.19%
$1.09
ASST
+19.20%
$1.49
PFE
-1.45%
$24.30
VHAI
0.00%
$0.00
RIVN
+24.05%
$15.50
LNAI
+60.07%
$1.33
PLUG
-8.36%
$2.52
NVDA
+1.26%
$201.21
RUBI
-54.72%
$0.27
SMX
+42.04%
$2.08
YDKG
-7.03%
$0.05
SLDP
+52.44%
$8.55
BYND
-2.25%
$1.30
AXDX
-61.36%
$0.03
PLTR
-0.75%
$189.30
GPUS
-7.02%
$0.34
TSLA
+4.39%
$463.77
F
+3.66%
$13.25
AMD
+3.62%
$259.11
ADAP
-15.14%
$0.05
DNN
-1.86%
$2.68
WTO
-5.83%
$0.04
PINS
-22.07%
$25.64
BITF
+2.60%
$3.94
BMNR
-7.93%
$39.46
INTC
+3.59%
$38.36
CIFR
+7.46%
$24.19
AAL
+6.79%
$13.51
NFE
+13.12%
$1.52
SMCI
-9.70%
$42.80
ETHD
-15.40%
$4.44
ONDS
-0.75%
$5.91
RXRX
-0.40%
$4.98
SOFI
+1.48%
$29.80
TEVA
+22.06%
$24.97
RMBL
+60.50%
$3.21
JOBY
-9.55%
$14.76
DVLT
-8.44%
$1.62
ADD
-25.47%
$0.05
ACHR
-0.15%
$9.54
T
+0.14%
$24.47
SRM
+53.27%
$10.30
BAC
-1.44%
$52.76
SNAP
+0.06%
$7.47
KVUE
+2.12%
$16.30
EPWK
-6.81%
$0.06
QS
+10.91%
$17.12
RIG
+0.38%
$3.91
FUBO
+9.10%
$4.01
TLRY
+2.41%
$1.27
VALE
+3.24%
$12.32
ZDAI
+18.33%
$0.54
NAKA
-11.88%
$0.78
KDLY
-11.88%
$0.78
IREN
+10.35%
$73.53
BTG
+1.00%
$4.04
CAN
+12.16%
$1.24
APLD
-5.50%
$31.06
APPS
+21.45%
$7.19
WLGS
-5.57%
$0.04
WULF
+0.39%
$15.07
U
+14.50%
$41.07
NVO
-0.87%
$47.82
MARA
+3.29%
$17.16
HIMS
+4.67%
$44.79
GRAB
-0.08%
$5.78
ETWO
0.00%
$3.30
RGTI
+4.81%
$36.87
RDHL
+13.88%
$1.23
BURU
-3.24%
$0.28
NIO
+3.00%
$7.37
PCG
+1.11%
$16.34
NOK
+0.70%
$6.85
COMP
+7.45%
$8.36
BTBT
+2.06%
$3.24
HTZ
-4.60%
$6.42
WBD
+1.77%
$23.00
MU
-7.10%
$218.03
BW
+36.89%
$5.12
AFMD
-34.94%
$0.18
NCLH
-0.01%
$18.78
IONZ
-8.42%
$4.09
HBAN
-0.65%
$15.27
CMBM
-12.34%
$2.84
AG
-7.48%
$10.69
AMZN
0.00%
$249.31
QBTS
+4.60%
$31.11
RIOT
-3.78%
$18.54
SOLT
-13.39%
$11.06
PLTD
+1.02%
$6.41
PLTZ
+3.12%
$6.25
AAPL
+0.20%
$270.58
NVTS
-7.60%
$9.66
BBD
+2.81%
$3.50
SOUN
+2.54%
$15.51
MSPR
-24.83%
$0.49
ABEV
+1.04%
$2.41
CMG
+1.15%
$32.10
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.